Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S.

Next Previous
Trial Profile

Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria; Malaria
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 31 Mar 2020 Results (n=45) assessing functional antibodies and protection against controlled human malaria infection challenge were published in the Journal of Infectious Diseases
    • 10 Feb 2018 Results of pooled analysis of this and other five phase II studies assessing relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections, published in the Vaccine.
    • 12 Jan 2010 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top